Tilson Financial Group Inc. Acquires New Holdings in Johnson & Johnson (NYSE:JNJ)

by · The Cerbat Gem

Tilson Financial Group Inc. bought a new position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 1,593 shares of the company’s stock, valued at approximately $258,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Tevis Investment Management raised its position in shares of Johnson & Johnson by 5.4% during the third quarter. Tevis Investment Management now owns 17,334 shares of the company’s stock worth $2,809,000 after acquiring an additional 884 shares during the last quarter. Cornerstone Wealth Group LLC raised its holdings in Johnson & Johnson by 1.3% during the 3rd quarter. Cornerstone Wealth Group LLC now owns 52,977 shares of the company’s stock worth $8,585,000 after purchasing an additional 687 shares during the last quarter. JFS Wealth Advisors LLC lifted its position in shares of Johnson & Johnson by 49.7% in the 3rd quarter. JFS Wealth Advisors LLC now owns 30,621 shares of the company’s stock worth $4,962,000 after purchasing an additional 10,160 shares during the period. SteelPeak Wealth LLC boosted its stake in shares of Johnson & Johnson by 9.6% in the 3rd quarter. SteelPeak Wealth LLC now owns 77,813 shares of the company’s stock valued at $12,610,000 after purchasing an additional 6,786 shares during the last quarter. Finally, Diversify Wealth Management LLC boosted its stake in shares of Johnson & Johnson by 18.4% in the 3rd quarter. Diversify Wealth Management LLC now owns 11,709 shares of the company’s stock valued at $1,942,000 after purchasing an additional 1,822 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Morgan Stanley lifted their target price on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. TD Securities dropped their price objective on Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Wells Fargo & Company upped their target price on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Sanford C. Bernstein lifted their target price on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Finally, Daiwa Capital Markets lowered shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Six investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $175.93.

Read Our Latest Research Report on JNJ

Insider Activity

In other news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $159.86 on Friday. The company’s 50 day moving average is $163.39 and its 200-day moving average is $155.35. The firm has a market cap of $384.88 billion, a P/E ratio of 23.13, a price-to-earnings-growth ratio of 2.85 and a beta of 0.52. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. During the same quarter in the prior year, the business posted $2.66 earnings per share. The business’s quarterly revenue was up 5.2% on a year-over-year basis. Sell-side analysts predict that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.10%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s payout ratio is presently 71.78%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Recommended Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).